Sanochemia Pharmazeutika AG
Notice
The data below are a snapshot taken at the time of the initial public offering and are not
updated regularly. For current information on a company, please go to
Investors/Companies.
| ISIN: | AT0000776307 |
| Symbol: | SAC |
| Trading segment: | Third Market |
| Market segment: | mid market |
| First day of trading: | February 26, 2010 |
| Category: | Ordinary Shares |
| Company profile: |
(Profile provided by the company)
Active pharmaceutical ingredients (APIs) such as galantamine, used in an Alzheimer’s drug, enabled the company to establish a foothold in the global pharmaceuticals market. Tolperisone is another development project from SANOCHEMIA’s research and development pipeline to go into production, from where it is currently marketed in Germany and Switzerland. Our R&D focus at present lies on innovative projects such as PVP hypericin, for the photodynamic diagnosis and treatment of bladder cancer, and Secrelux®, a pancreatic function diagnostic. The sale of clinical diagnostics via the subsidiary SANOCHEMIA Diagnostics represents another profitable area of operations. This division’s entry into the MRT imaging agents market in 2007 has provided access to the most important segment of the market for imaging diagnostics. The manufacture and marketing of radiological products has now developed to become one of the group's fastest growing areas of operation. |